According to filings with the U.S. Securities and Exchange Commission, Kindra is raising up to $2,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Catherine Balsam-Schwaber played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Kindra
Kindra develops science-driven, physician-backed, estrogen-free solutions targeting the top pain points of the 34+ symptoms of menopause; plus provides expert guidance, resources, and support to navigate a critical period in a womans health journey. Kindra is the fastest growing direct to consumer menopause company in the US, helping to build the much needed category of effective products, education, and community for women navigating mid-life health and wellness. Kindra serves women in all phases of the menopause journey, helping to prepare for, manage, and embrace their natural hormonal shifts, while harnessing the insight and expertise of interdisciplinary womens health experts and board certified OB/GYNs. At the intersection of clinically-studied advancements in formulation, critical insight from medical advisors, leading chemists, and robust consumer studies, Kindras Innovation Lab delivers patent-pending solutions that target some of the most disruptive symptoms. Kindras community of women are finding both support and relief – 55,000 women have completed our assessment, leading to personalized menopause care regimens.

To learn more about Kindra, visit http://ourkindra.com/

Contact:
Catherine Balsam-Schwaber, Chief Executive Officer
646-425-5558

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.